Steven Cohen Lyell Immunopharma, Inc. Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 6,800 shares of LYEL stock, worth $9,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,800Holding current value
$9,860% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding LYEL
# of Institutions
128Shares Held
144MCall Options Held
0Put Options Held
5.9K-
Mwg Management Ltd. Washington, DC20.2MShares$29.2 Million33.29% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$21.9 Million19.02% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$21.9 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.9MShares$20.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.4MShares$19.4 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $359M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...